Menu

RHB-104 (GI/Inflammation)

RHB-104 is a potentially groundbreaking, proprietary antibiotic combination therapy in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties.

RHB-104 is based on increasing evidence supporting the hypothesis that Crohn’s disease is caused by the Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients. The RHB-104 formulation was originally developed by Professor Thomas Borody, a leading innovator of therapeutic approaches to treating gastrointestinal tract diseases, who also developed the original triple therapy for peptic ulcer disease associated with H. pylori.

RHB-104 is being developed for multiple indications, including:

  • Crohn's disease - positive top-line results from a first Phase III study for Crohn's disease (MAP US study) were announced in July 2018

  • Multiple sclerosis - a Phase IIa proof of concept study for multiple sclerosis was completed in Israel with encouraging top-line final results announced December 2016